ALLERGAN, INC. 
By CORAL SPRINGS, Florida, January 31, 2013 /PRNewswire/ --
Crown Marketing Pharmaceuticals (OTC: CWNM [http://finance.yahoo.com/q?s=cwnm&ql=1 ]) announced today that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin. The most common adverse effects of Metformin are gastrointestinal upset including diarrhea, cramps, nausea and vomiting. Crown Marketing Pharmaceuticals (OTC: CWNM [http://finance.yahoo.com/q?s=cwnm&ql=1 ]) believes it can significantly reduce or eliminate these effects with its patented technology.
Patients also have issues about the taste and odor associated with the medication. Common complaints are that it "smells fishy" and can leave a metallic taste in the mouth. This is critical because it impacts patient compliance-if it tastes or smells bad, patients oftentimes will not take the medication as directed. Crown's CDDT can overcome these issues due to its novel, diffusion based design and its impermable coating. According to IMS figures, the total market sales for all forms of Metformin were $1.6 billion, with sales of Metformin extended-release formulation alone accounting for over $460 million last year.
Metformin is an pharmaceutical oral diabetes medicine that helps control blood sugar levels originally sold as Glucophage. Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes. One of the more common long-term complications of diabetes is diabetic renal disease ("renal" refers to the kidneys). Also known as diabetic nephropathy, this condition is a result of direct vascular abnormalities that accompany diabetes. Keryx Biopharmaceuticals Inc. (NASDAQ: KERX [http://finance.yahoo.com/q?s=kerx&ql=1 ]) announced this week that its kidney disease drug, Zerenex, is also receiving positive signs as it has performed better than a placebo in late-stage clinical trials. The New York company said Monday that Zerenex showed a "highly statistically significant" change in serum phosphorus levels compared with a placebo in patients with advanced kidney failure who were on dialysis. Keryx Biopharmaceuticals Inc. (NASDAQ: KERX [http://finance.yahoo.com/q?s=kerx&ql=1 ]) closed up yesterday at $8.49 per share on large trading volume over 49.1Million shares traded.
The Global Pharmaceutical & Biotechnology sector continues to remain attractive, as cost containment initiatives, restructuring/deconsolidation, share repurchase program, M&A, emerging market growth potential and dividend policy continue to be encouraging. Over the next few years, the growth of the industry would be shaped up by a battle between fundamental growth drivers (Value added innovation) versus regulatory pressures to contain costs. In Merger & Acquisition news, MAP Pharmaceuticals, Inc. (NASDAQ: MAPP [http://finance.yahoo.com/q?s=mapp&ql=1 ]) is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX(R), an orally inhaled investigational drug for the acute treatment of migraine. Allergan, Inc. (NYSE: AGN [http://finance.yahoo.com/q?s=agn&ql=1 ]) inked a deal with MAP Pharmaceuticals, Inc. (NASDAQ: MAPP [http://finance.yahoo.com/q?s=mapp&ql=1 ]) to acquire the latter. As per the terms of the deal, Allergan will acquire all the shares of MAP Pharmaceuticals for $25.00 per share. The offer price represents premium of 60% over MAP Pharmaceuticals' closing price back on Jan 22, 2012.
Another leader in the sector, Amarin Corporation (NASDAQ: AMRN [http://finance.yahoo.com/q?s=amrn&ql=1 ]) was originally a small British drug delivery company, which evolved into a cardiovascular drug development company and is now among the more promising biopharmaceutical companies in the US. Vascepa (icosapent ethyl) for treatment of hypertriglyceridemia is Amarin's first FDA approved product, whose market introduction was announced by the company on January 24, 2013. Hypertriglyceridemia refers to high blood level of triglycerides, a blood fat that contributes to cardiovascular problems.
FinancialNewsMedia.com [http://www.financialnewsmedia.com ] is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For disseminating this release, FNMG was not compensated by any companies mentioned herein this release. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE AND WAS NOT COMPENSATED BY ON OTHER COMPANY INCLUDED HEREIN.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC [http://www.financialnewsmedia.com ]
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.comSOURCE FN Media Group LLC
